Stevens v. Parke, Davis & Co.

507 P.2d 653, 9 Cal. 3d 51, 107 Cal. Rptr. 45, 94 A.L.R. 3d 1059, 1973 Cal. LEXIS 175
CourtCalifornia Supreme Court
DecidedMarch 14, 1973
DocketL.A. 30030
StatusPublished
Cited by265 cases

This text of 507 P.2d 653 (Stevens v. Parke, Davis & Co.) is published on Counsel Stack Legal Research, covering California Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Stevens v. Parke, Davis & Co., 507 P.2d 653, 9 Cal. 3d 51, 107 Cal. Rptr. 45, 94 A.L.R. 3d 1059, 1973 Cal. LEXIS 175 (Cal. 1973).

Opinion

Opinion

SULLIVAN, J.

In this action for damages for wrongful death, plaintiffs appeal from an order granting defendants Parke, Davis & Company (Parke, Davis) and A. J. Beland, M.D. (Dr. Beland), a new trial on the issue of damages. Defendant Parke, Davis appeals from the judgment entered on the verdict in favor of plaintiffs and against Parke, Davis, and from the order denying said defendants’ motion for judgment notwithstanding the verdict. 1

Plaintiffs Janet, Suzanne and Kennan Stevens are the surviving children, and plaintiff John Stevens is the surviving husband, of Phyllis Stevens who died allegedly as a result of ingesting the drug Chloromycetin which was manufactured by Parke, Davis and prescribed by Dr. Beland. Since her youth, Mrs. Stevens had suffered from a chronic lung condition that was both discomforting and conducive to lung infection. She was nevertheless able to function normally as a housewife and mother of three children, and planned, after receiving a teaching credential, to work part-time as a substitute teacher.

In 1964, Mrs. Stevens sought the aid of Dr. Beland to see if something could be done for her lung condition that would make it easier for her to teach. Dr. Beland’s initial physical examination disclosed that Mrs. Stevens, then 38 years of age, was of generally good health. However, X-rays confirmed that she was suffering from a lung condition diagnosed as bilateral bronchiectasis, an anatomical derangement in the bronchial tree that increases the susceptibility to lung infection. To alleviate this disorder, Dr. Beland recommended and eventually performed surgery on September 1,1964.

Two days after the operation, Dr. Beland prescribed the first of six administrations of Chloromycetin, a broad-spectrum antibiotic used to *57 guard against infection. The final dose was administered on November 20, 1964. Mrs. Stevens failed to improve following the surgery, and in June 1965 she was referred to Dr. Kumick, a hematologist.

Dr. Kumick found Mrs. Stevens to be suffering from bone marrow failure (aplastic anemia), that is, the inability of bone marrow to produce blood cells in sufficient numbers to ward off general infection. He testified that, in his opinion, this condition was caused by the administration of Chloromycetin, which has a history of causing aplastic anemia in certain patients and is thus considered by members of the medical profession to be a dangerous drug. 2 Mrs. Stevens died of pneumonia on December 25, 1965, as a result of the inability of her body to produce the necessary blood cells to resist infection.

We summarize the evidence in the record bearing upon the development and promotion of the above antibiotic. Chloromycetin is the trade name give by Parke, Davis to the antibiotic drug chloramphenicol. Discovered in 1946, the drag first reached the market in 1949 after tests by Parke, Davis as to its effectiveness. Shortly thereafter, articles began appearing in medical journals, associating Chloromycetin with blood dyscrasias (disorders) such as aplastic anemia. In 1952, the United States Food and Drag Administration (FDA), after its own investigation, allowed continued sale of the drug but directed Parke, Davis to include the following warning on each label of the drug: “Warning — Blood dyscrasias may be associated with intermittent or prolonged use. It is essential that adequate blood studies be made.” 3 Shortly thereafter, Parke, Davis, dis *58 tributed “Dear Doctor" letters to the medical profession, summarizing the results of the FDA investigation.

Notwithstanding the FDA’s efforts to require adequate warnings concerning the use of Chloromycetin, Parke, Davis retained considerable latitude to promote and advertise its drug, in' some instances without any warning whatsoever. Following the FDA directive of 1952, Parke, Davis sent letters to its salesmen that appeared to minimize the dangers of the drug. 4 Its salesmen continued concentrated promotions of Chloromycetin from 1952 through the period covered in this case. These promotions included personal visits to doctors by “detail men" urging them to use the drug; no verbal warnings were given on these occasions, although brochures left with the physicians apparently included written warnings. Other promotional methods included the dissemination of calendars, rulers and other “give-aways” carrying the name Chloromycetin, but no warning language. Full-page “reminder ads” were published in medical journals, but contained no reference to the possibility of harmful side effects. 5 Nor did Parke, Davis include any warning concerning Chloromycetin in the description of the drug contained in the 1962 edition of the Physicians’ Desk Reference (PDR), an encyclopedia of drugs widely used by physicians. 6

Plaintiffs brought the present action for damages for the wrongful death of Phyllis Stevens allegedly caused by the administration of Chloromycetin. The complaint named Parke, Davis and Dr. Beland as defendants, and stated three separate causes of action as to each: liability based on negligence (of Parke, Davis for overpromotion of the drug, and of Dr. Beland, for lack of due care in prescribing it); liability based on breach of implied *59 warranty; and strict liability in tort. After the presentation of plaintiffs case, the trial court granted Parke, Davis’ motion for nonsuit as to the second and third causes of action, but denied it as to the first cause of action based on negligence. 7 The court also denied Dr. Beland’s motion for nonsuit. 8

The jury returned a verdict in favor of plaintiffs and against both defendants in the amount of $400,000. The trial court, however, ordered remittitur of the verdict to the sum of $64,673.42 on the ground that excessive damages were awarded due to the “prejudice and passion” of the jury. Plaintiffs’ failure to consent to the remission resulted in an order granting defendants’ motions for new trial solely on the issue of damages. The instant appeals followed.

I

We first take up plaintiffs’ appeal from the order granting a new trial. Each of the defendants separately moved for a new trial on several grounds. The trial judge denied the motions on the issue of liability but granted a new trial as to both defendants solely on the issue of damages. An examination of the court’s order, which we set forth in relevant part in the margin, 9 discloses that it was based on the sole ground that the damages were excessive. (Code Civ. Proc., § 657, subd. 5.) 10 Plaintiffs con *60 tend that this order should be reversed because it fails to contain an adequate specification of reasons in compliance with Code of Civil Procedure section 657. We agree.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Medel v. Oceanic Companies CA4/1
California Court of Appeal, 2024
Hilltop Group, Inc. v. County of San Diego
California Court of Appeal, 2024
People v. Davis CA4/1
California Court of Appeal, 2023
Woodlief v. Woodlief CA1/5
California Court of Appeal, 2023
People v. Faatai CA2/3
California Court of Appeal, 2023
People v. Rivera CA2/3
California Court of Appeal, 2020
City of Modesto v. Dow Chemical Co.
California Court of Appeal, 2018
Webb v. Special Electric Co., Inc.
370 P.3d 1022 (California Supreme Court, 2016)
People v. Nicolas CA1/3
California Court of Appeal, 2016
DMF Trucking v. Colmac Energy CA4/1
California Court of Appeal, 2015
Hanson v. Cable CA1/3
California Court of Appeal, 2015
Ybarra v. Lindgren CA3
California Court of Appeal, 2014
Lovelace v. Pneumo Abex CA3
California Court of Appeal, 2014
People v. McGuire CA1/3
California Court of Appeal, 2014
People v. Meyers CA1/3
California Court of Appeal, 2014
Collin v. CalPortland Co. CA3
228 Cal. App. 4th 582 (California Court of Appeal, 2014)
Taubman v. U.S. Bank N.A. CA2/7
California Court of Appeal, 2014
Key v. City of San Mateo Police Dept. CA1/3
California Court of Appeal, 2014
People v. Parsons CA1/3
California Court of Appeal, 2014
In Re Zyprexa Products Liability Litigation
649 F. Supp. 2d 18 (E.D. New York, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
507 P.2d 653, 9 Cal. 3d 51, 107 Cal. Rptr. 45, 94 A.L.R. 3d 1059, 1973 Cal. LEXIS 175, Counsel Stack Legal Research, https://law.counselstack.com/opinion/stevens-v-parke-davis-co-cal-1973.